These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6414198)

  • 21. [The protective properties of Pseudomonas aeruginosa anatoxin].
    Dziuban NF; Podgornaia LG
    Mikrobiol Zh (1978); 1985; 47(2):83-6. PubMed ID: 3939835
    [No Abstract]   [Full Text] [Related]  

  • 22. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens.
    Collins MS; Ladehoff D; Mehton NS
    Antibiot Chemother (1971); 1991; 44():185-95. PubMed ID: 1801636
    [No Abstract]   [Full Text] [Related]  

  • 24. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
    Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficiency of Pseudomonas aeruginosa vaccines in the prevention and treatment of Pseudomonas infections in burned patients.
    Ionescu A; Meitert E; Vasiliu S; Meitert T; Sima F; Savulian C; Milicescu S
    Arch Roum Pathol Exp Microbiol; 1981; 40(4):323-32. PubMed ID: 6803737
    [No Abstract]   [Full Text] [Related]  

  • 27. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. For Pseudomonas aeruginosa, stealth is no longer enough.
    Brubaker RR
    Nat Med; 1999 Apr; 5(4):378-9. PubMed ID: 10202921
    [No Abstract]   [Full Text] [Related]  

  • 29. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ; Sadoff JC; Que JU
    Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
    [No Abstract]   [Full Text] [Related]  

  • 30. Epidemiological and immunobiological implications of Pseudomonas aeruginosa epidemiological markers.
    Meitert T; Meitert E
    Arch Roum Pathol Exp Microbiol; 1981; 40(1):5-23. PubMed ID: 6821022
    [No Abstract]   [Full Text] [Related]  

  • 31. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experimental vaccinal prophylaxis of Pseudomonas aeruginosa burn sepsis].
    Bandman OA; Stanislavskiĭ ES; Kholodkova EV; Ivanova TV; Salov VF
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Jul; (7):59-62. PubMed ID: 2510430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.
    Meitert E; Meitert T; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):105-14. PubMed ID: 6816188
    [No Abstract]   [Full Text] [Related]  

  • 34. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research.
    Pier GB
    Antibiot Chemother (1971); 1985; 36():157-67. PubMed ID: 3923913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization against Pseudomonas aeruginosa: the effects of serotype and virulence in mouse protection tests.
    Markman B; Fall-Persson M; Salenstedt CR
    J Biol Stand; 1982 Oct; 10(4):319-28. PubMed ID: 6818231
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of Pseudomonas aeruginosa multicomponent vaccine in patients with intractable lower respiratory tract infection associated with diffuse panbronchiolitis].
    Yoshimura K; Tachibana A; Nakatani T; Chonabayashi N; Nakamori Y; Nakata K; Tanimoto H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1986 Jun; 24(6):625-32. PubMed ID: 3095578
    [No Abstract]   [Full Text] [Related]  

  • 37. Current status of Pseudomonas aeruginosa vaccine.
    Michelim L; Medeiros GS; Zavascki AP
    Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of exoenzymes and exotoxin in the pathogenicity of Pseudomonas aeruginosa and the development of a new vaccine.
    Homma JY
    Jpn J Exp Med; 1980 Jun; 50(3):149-65. PubMed ID: 6776324
    [No Abstract]   [Full Text] [Related]  

  • 39. Experimental immunization with attenuated mutants of Pseudomonas aeruginosa.
    Syeklocha D
    Can J Microbiol; 1973 May; 19(5):573-80. PubMed ID: 4196781
    [No Abstract]   [Full Text] [Related]  

  • 40. [Combined Staphylococcus-Proteus-Pseudomonas vaccine. II. The toxicity of the vaccine in "chronic" experiments and its ability to protect animals against Proteus and Staphylococcus infections].
    Kreĭnin LS; Egorova NB; Stanislavskiĭ ES; Kaverina KG; Levina LA
    Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):87-92. PubMed ID: 6410625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.